Market Overview

Diabetes is said as a national disease because so many people are suffering from it. The diabetes market in this research has targeted the following two markets: 1) self-monitoring of blood glucose (SMBG) devices and related products (SMBG devices & sensors, based on the shipment values at manufacturers) and 2) diabetes medicines (hypoglycemic agents and insulin preparation, based on NHI drug prices). The diabetes market size (total two categories) is projected to generate 681,000 million yen in FY2022.

When observing the details, SMBG (self-monitoring of blood glucose) devices market has continue shrinking from leveling off status in recent years, against the backdrop of fiercer price competition of the devices themselves, and the status of insulin therapy introductions. On the contrary, hypoglycemic agents including sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are on an expansion trend in the diabetes medicines market.

Noteworthy Topics

While CGM Devices Expanded in SMBG Device Market, New Products of GLP-1 Receptor Agonists Expanded Sales in Diabetes Medicines Market

The SMBG devices market has been on an expansion tendency, due to a series of launch of CGM (Continuous Glucose Monitoring) devices that automatically tracks blood glucose levels throughout the day and night, together with insurance coverage expansion.

In the diabetes medicines market, the market of SGLT2 inhibitors, based on the NHI drug prices, seemed to have exceeded 100,000 million yen in FY2021, partly because insurance coverage expansion for existing products. For GLP-1 receptor agonists, sales expansion in new products such as oral drugs was considered to have contributed.

Future Outlook

The diabetes market size (total two categories) is projected to exceed 700,000 million yen by FY2025, but is expected to remain at 692,300 million yen in FY2026. While the SMBG devices market is likely to be on a slight declining tendency, the diabetes medicines market is projected to be on a slight rise, taking into account of the influence of NHI drug price revisions. Although SGLT2 inhibitors and GLP-1 receptor agonists are expected to show favorable sales, expiration of patents and NHI drug price revisions are likely to influence the market

Research Outline